Shares of AngioDynamics (NASDAQ:ANGO) were unchanged in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 83.33% year over year to $0.01, which beat the estimate of ($0.02).
Revenue of $72,770,000 rose by 3.95% year over year, which beat the estimate of $67,350,000.
Looking Ahead
AngioDynamics reaffirmed FY21 adjusted EPS guidance of $0.00 to $0.05 and sales forecast of $278 million to $284 million.
Conference Call Details
Date: Jan 07, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/r4ork9sm
Recent Stock Performance
Company's 52-week high was at $17.24
52-week low: $7.48
Price action over last quarter: Up 34.25%
Company Description
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
https://finance.yahoo.com/news/angiodynamics-q2-earnings-insights-121705391.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.